Does dapagliflozin reduce the incidence of death from any cause or worsening of heart failure in older adults with aortic stenosis undergoing TAVI who are at high risk for heart-failure events?
Dapagliflozin significantly reduces the composite of all-cause mortality or worsening heart failure in high-risk older adults undergoing TAVI.
Among older adults with aortic stenosis undergoing TAVI who were at high risk for heart-failure events, dapagliflozin resulted in a significantly lower incidence of death from any cause or worsening of heart failure than standard care alone. (Funded by Instituto de Salud Carlos III and others; ClinicalTrials.gov number, NCT04696185.).
Raposeiras‐Roubín et al. (Sat,) studied this question.